These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2887758)

  • 1. Aluminium-related bone disease and haemodialysis.
    Seyfert UT; Didion K; Albert FW
    Lancet; 1987 Aug; 2(8556):456. PubMed ID: 2887758
    [No Abstract]   [Full Text] [Related]  

  • 2. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinetics of aluminium removal by desferrioxamine VIA hemodialysis in a case with aluminium bone disease.
    Terao N; Sizuki M; Ando Y; Kato K; Asano Y; Hosoda S; Suka T
    Nihon Jinzo Gakkai Shi; 1985 Sep; 27(9):1305-12. PubMed ID: 4087551
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone histologic response to deferoxamine in aluminum-related bone disease.
    Andress DL; Nebeker HG; Ott SM; Endres DB; Alfrey AC; Slatopolsky EA; Coburn JW; Sherrard DJ
    Kidney Int; 1987 Jun; 31(6):1344-50. PubMed ID: 2441107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persisting aluminium-related bone disease after cadaveric renal transplantation.
    Nicholas JC; Dawes PT; Davies SJ; Freemont AJ
    Nephrol Dial Transplant; 1999 Jan; 14(1):202-4. PubMed ID: 10052510
    [No Abstract]   [Full Text] [Related]  

  • 7. [Aluminum in chronic renal failure].
    Głuszek J; Adamczak H
    Rocz Panstw Zakl Hig; 1993; 44(1):43-8. PubMed ID: 8235341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prurigo nodularis and aluminium overload in maintenance haemodialysis.
    Brown MA; George CR; Dunstan CR; Kalowski S; Corrigan AB
    Lancet; 1992 Jul; 340(8810):48. PubMed ID: 1351616
    [No Abstract]   [Full Text] [Related]  

  • 11. Osteomalacia and bone disease arising from aluminum.
    Coburn JW; Norris KC; Nebeker HG
    Semin Nephrol; 1986 Mar; 6(1):68-89. PubMed ID: 3110896
    [No Abstract]   [Full Text] [Related]  

  • 12. Aluminum-associated bone disease: considerations on the pathogenesis and the effects of deferoxamine treatment.
    Kurokawa K; Marumo F; Ogura Y; Ono T; Suzuki M
    J UOEH; 1987 Mar; 9 Suppl():133-9. PubMed ID: 3602744
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients.
    Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA
    Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 15. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodialysis related osteomalacia: a staining method to demonstrate aluminium.
    Buchanan MR; Ihle BU; Dunn CM
    J Clin Pathol; 1981 Dec; 34(12):1352-4. PubMed ID: 6173400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aluminum-related bone disease. Correlation between symptoms, osteoid volume, and aluminum staining.
    Connor MO; Garrett P; Dockery M; Donohoe JF; Doyle GD; Carmody M; Dervan PA
    Am J Clin Pathol; 1986 Aug; 86(2):168-74. PubMed ID: 2426938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone disorders in children with chronic renal insufficiency exposed to high ingestion of aluminum].
    Gordillo-Paniagua G; Valencia-Mayoral P; Mercado L; Medina-Mercado M
    Bol Med Hosp Infant Mex; 1990 May; 47(5):336-41. PubMed ID: 2390188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a cutoff value of desferrioxamine infusion test for bone aluminium deposits in hemodialyzed patients.
    Piccoli A; Nordio M; Andriani M; Borsatti A
    Nephron; 1986; 44(2):153-4. PubMed ID: 3774078
    [No Abstract]   [Full Text] [Related]  

  • 20. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.